Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Alterity Therapeutics Investor Presentation

April 10, 2019 Kerry Rowe

Alterity Therapeutics Investor Presentation 10 April 2019

Post navigation

Alterity Therapeutics Launches to Asian Investors

Alterity Therapeutics presents at the American Academy of Neurology Annual Meeting

Related Posts

Preliminary Final Report (Appendix 4E)

August 27, 2015

The Lancet Neurology publishes Prana’s Huntington’s Disease Trial

November 18, 2014

Alterity Therapeutics meeting with US FDA provides development pathway for ATH434

June 30, 2020May 19, 2021

Recent Posts

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy
Alterity to Present at Life Sciences Investor Forum
Alterity Therapeutics to Present at the GCFF Virtual Conference 2022 – Investing in Healthcare
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy
Alterity Therapeutics to Participate in the Benchmark Company Healthcare House Call Conference

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065